perhaps their sticking to the plan pf being as less dilutive to shareholders as they can be. Picking up a new drug will cost alot more than what they potentially acquiring. A new drug will have CR after CR at esxh stage that would be very dilutive
FTT Research, page-254
Add DLM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| DLM (ASX) Chart |
Day chart unavailable